Showing 4781-4790 of 8208 results for "".
- Daavlin, HealthLens Partner to Increase Phototherapy Accesshttps://practicaldermatology.com/news/daavlin-healthlens-partner-to-increase-phototherapy-access/2460232/Daavlin, a leading U.S. manufacturer of phototherapy units, is teaming up with HealthLens to increase access to phototherapy via teledermatology. Appointment wait times for dermatology services have increased by 46 percent since 2009, according to
- Proscia and Johns Hopkins School of Medicine Collaborate to Bring AI Applications to High-Impact Diseases and Specialties in Pathologyhttps://practicaldermatology.com/news/proscia-and-johns-hopkins-school-of-medicine-collaborate-to-bring-ai-applications-to-high-impact-diseases-and-specialties-in-pathology/2460231/Proscia, a provider of AI-enabled digital pathology software, and Johns Hopkins School of Medicine, one of the leading academic medical centers in the US, will collaborate on the development of computational applications that incorporate artificial intelligence (AI) to advance the practice of pat
- Norfolk Dermatologist Recognized for Increasing Accessibility for Patientshttps://practicaldermatology.com/news/norfolk-dermatologist-recognized-for-increasing-accessibility-for-patients/2460227/Dermatologist Abby Van Voorhees, MD, FAAD, is an American Academy of Dermatology Patient Care Hero for her leadership at the Rapid Access Clinic at the Eastern Virginia Medical School Dermatology Practice in Norfolk, Va. The Eastern Virginia Medical School Dermatology practice allo
- NavaDerm Partners Adds Dan Wechsler as Executive Chairmanhttps://practicaldermatology.com/news/navaderm-partners-adds-dan-wechsler-as-executive-chairman/2460225/Dan Wechsler is the new Executive Chairman of NavaDerm Partners, a Northeast-focused dermatology services company and portfolio company of BelHealth Investment Partners, a New York-based healthcare private equity firm. Wechs
- Revance Files BLA for DAXIhttps://practicaldermatology.com/news/revance-files-bla-for-daxi/2460224/Revance Therapeutics, Inc. has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for DaxibotulinumtoxinA for Injection (DAXI) in the treatment of moderate to severe glabellar lines. Under the current Pres
- Keloid Breakthrough: Mount Sinai Researchers Show Keloid Shrinkage with Dupilumabhttps://practicaldermatology.com/news/keloid-breakthrough-mount-sinai-researchers-show-keloid-shrinkage-with-dupilumab/2460223/Keloid lesions exhibit increased IL-4/IL-13 signaling and respond to Th2-targeting dupilumab therapy, Mount Sinai researchers report. Researchers, led by Emma Guttman-Yassky, MD, PhD, Vice Chair, Department of Dermatology at the Icahn School of Medicine at Mount Sinai in New York,
- Dermatologists Issue Guidelines for Opioid Management Following 87 Common Procedureshttps://practicaldermatology.com/news/dermatologists-issue-guidelines-for-opioid-management-following-87-common-procedures/2460219/New dermatologic procedure-recommendations for opioid management seek to help curtail the opioid epidemic and reduce the number of opioid overdose deaths. The new consensus statement was developed by a group of 40 board-certified dermatologists, including Mohs micrographic surgeons, der
- Celebrate National Botox Day on November 20, 2019https://practicaldermatology.com/news/celebrate-national-botox-day-on-november-20th-2019/2460218/Mark your calendars: November 20, 2019 will be the first-ever National Botox Cosmetic Day. Why Nov. 20? It is the busiest day on record for booking Botox cosmetic treatments in the US. And to commemorate it, Allergan is offering an exclusive deal for one day only where patien
- Melanoma Rates Drop Sharply Among Teens, Young Adultshttps://practicaldermatology.com/news/melanoma-rates-drop-sharply-among-teens-young-adults/2460217/Cases of melanoma among U.S. adolescents and young adults declined markedly from 2006 to 2015 - even as the skin cancer's incidence continued to increase among older adults and the general population during the span, new research in JAMA Dermatology shows. The finding,
- Allergan Pays Exicure $25M upfront in Collaboration Deal to Develop Hair Loss Treatmenthttps://practicaldermatology.com/news/allergan-pays-exicure-25m-upfront-in-collaboration-deal-to-develop-hair-loss-treatment/2460216/Allergan Pharmaceuticals International Limited has entered into a global collaboration agreement with Exicure to discover and develop novel treatments for hair loss disorders based on Exicure’s proprietary SNA technology. Allergan will receive exclusive access and options to licen